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Understanding inter-individual differences in stress response
requires the explanation of genetic influences at multiple pheno-
typic levels, including complex behaviours and the metabolic res-
ponses of brain regions to emotional stimuli. Neuropeptide Y
(NPY) is anxiolytic1,2 and its release is induced by stress3. NPY is
abundantly expressed in regions of the limbic system that are
implicated in arousal and in the assignment of emotional valences
to stimuli and memories4–6. Here we show that haplotype-driven
NPY expression predicts brain responses to emotional and stress
challenges and also inversely correlates with trait anxiety. NPY
haplotypes predicted levels of NPY messenger RNA in post-
mortem brain and lymphoblasts, and levels of plasma NPY.
Lower haplotype-driven NPY expression predicted higher
emotion-induced activation of the amygdala, as well as diminished
resiliency as assessed by pain/stress-induced activations of endo-
genous opioid neurotransmission in various brain regions. A
single nucleotide polymorphism (SNP rs16147) located in the pro-
moter region alters NPY expression in vitro and seems to account
for more than half of the variation in expression in vivo. These
convergent findings are consistent with the function of NPY as an
anxiolytic peptide and help to explain inter-individual variation in
resiliency to stress, a risk factor for many diseases.
Variation in stress resiliency influences many human characteris-
tics, including both normal and pathological behaviour7.
Maladaptive responses to stress are critical in the development of
many psychiatric disorders, including mood and anxiety disorders8,9.
Anxiety and emotionality (neuroticism) are moderately to highly
heritable traits (40–60%) but are also strongly influenced by expo-
sures to stress in a pattern consistent with gene–environment inter-
action10. These observations point to the importance of genes that
modulate the effects of stress. Genes—such as the serotonin trans-
porter—that have so far been implicated in emotional responses have
small effects on complex behavioural traits11, but larger effects on the
metabolic responses of the brain to emotional stimuli accessed by
brain imaging12–14.
We evaluated effects of neuropeptide NPY on emotion and stress
resiliency using a haplotype-based approach intended to capture
effects of unknown loci or locus combinations. We analysed func-
tionally grouped NPY haplotypes against a complex behaviour, trait
anxiety, and also on intermediate phenotypes accessed by two differ-
ent brain imaging modalities in which gene effects might be more
strongly manifested. An NPY seven-marker panel (Supplementary
Fig. 1a) genotyped in 516 Finnish Caucasians captured the major
haplotypes and linkage disequilibrium features observed in the
International HapMap Project (http://www.hapmap.org). A block
of strong pairwise linkage disequilibrium encompasses 70% of the
gene and extends from the 59 region to exon 3 (Supplementary Fig.
1b). Five haplotypes (H1–H5) account for 93.8% of chromosomes in
this block (Fig. 1a).
We observed haplotype-driven NPY mRNA expression in post-
mortem brain (US Caucasians, Miami sample) by detecting the dif-
ferential expression of alleles at single nucleotide polymorphism
(SNP) rs5574 C/T, selected because of its high frequency and location
in the transcript. Of these 28 samples, chosen because all were
heterozygous for rs5574, 16 (57%) showed differential allele expres-
sion at an allele ratio of more than 1.2, in either direction. H1 and H4
were low-expression haplotypes, H2 was high, H3 was intermediate
and H5 was unclassified because only two H1/H5 heterozygous brains
were available (Fig. 1b). This expression-based functional classifica-
tion is consistent with a cladistically based clustering of haplotypes,
indicating that expression variation is linked to gene ancestry (Fig. 1a).
The effects on expression of the more common H1, H2 and H3
haplotypes were verified in 47 lymphoblastoid cell lines derived from
healthy Finnish men (Fig. 1c) representing the six common diplotypes
(72% of all diplotypes). On the basis of lymphoblast NPY mRNA
levels, the expression value for each haplotype was calculated by
regression analysis. Expression values for the six common diplotypes
were well predicted under a co-dominant model and had a threefold
range (see Supplementary Fig. 2 for details). Diplotypes were clustered
into three expression groups: low (LL: H1/H1), intermediate (LH: H1/
H3, H3/H3 and H1/H2) and high (HH: H2/H3 and H2/H2) (Fig. 1c).
We applied this grouping in subsequent analyses. Two loci, rs3037354
and rs16147, which differentiate the three common haplotypes (see
Fig. 1a), correlated with expression (Supplementary Fig. 3). However,
NPY haplotypes accounted for more variation. Finally, haplotype-
predicted NPY expression was correlated with plasma NPY peptide
levels available in a US sample (New Haven) in both controls (n 5 24)
and alcoholic patients (n 5 18) sampled during a no-stress condition.
Individuals with the low-expression LL diplotype had lower NPY
levels than those with high-expression HH diplotypes; individuals
with LH diplotypes were intermediate (P , 0.0001 in controls and
P 5 0.0074 in alcoholic patients; Fig. 1d).
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These common, functionally significant NPY haplotypes were
evaluated for their effect on brain responses to emotion and stress.
Amygdala activation in response to threat-related facial expressions
and other provocative stimuli predicts affective arousal, including
anxiety responses15,16. We employed a widely used functional mag-
netic resonance (fMRI) probe12,17 to assess whether NPY diplotypes
predicted amygdala reactivity to threat-related facial expressions in
71 healthy volunteers (Pittsburgh sample). This model has been used
to identify greater amygdala reactivity in individuals possessing the
lower-transcribing allele of the serotonin-transporter-linked poly-
morphic region (5-HTTLPR)12,18. As shown in Fig. 2, amygdala
activation in individuals with the low-NPY-expression (LL) diplo-
type was higher than in those with the high-expression (HH) diplo-
type (P 5 0.003). NPY diplotype predicted amygdala reactivity in an
allele-dosage fashion, and it accounted for 9% of the variance in the
fMRI amygdala response to emotional challenge. Task-related
hippocampal activation was similarly predicted in an allele-dosage
fashion (P 5 0.006; Fig. 2). Functional interactions of the amygdala
and hippocampus are crucial for emotional memories, and long-
lasting changes in hippocampal architecture are induced by stress19.
We also tested the ability of NPY haplotypes in a model of physical
and emotional stress involving moderate levels of sustained muscular
pain. This physical and emotional stress activates endogenous opioid
neurotransmission in regions of the brain that regulate pain, stress
and emotion20,21. Endogenous opioid release suppresses pain, stress
and anxiety-like responses in animal models22,23 and humans21. The
behavioural effects of NPY are mediated, at least in part, through
interactions with the endogenous opioid system24,25. We measured
endogenous opioid release by decreases in the availability of m-opioid
receptors in vivo during the painful stressor, quantified by means of
positron emission tomography (PET) with the selective m-opioid
receptor radiotracer [11C]carfentanil20,21 (see Supplementary
Methods for details). In 35 healthy volunteers (Ann Arbor sample),
we found that highly expressed NPY diplotypes predicted signifi-
cantly higher levels of stress-induced m-opioid system activation in
several brain regions (Fig. 3 and Supplementary Table 1) including
prefrontal cortex, posterior insula, medial and lateral thalamus, vent-
ral basal ganglia (ventral caudate, ventral putamen and nucleus
accumbens) and amygdala (analysis of variance (ANOVA),
P , 0.05 after correction for multiple comparisons). NPY diplotype
accounted for 13% of the variance in activation of m-opioid neuro-
transmission in the amygdala, 18–35% of the variance in prefrontal
cortex, thalamus and nucleus accumbens, and 37% of the variance in
posterior insular cortex. In comparison with its effects on the activa-
tion of endogenous opioid neurotransmission by painful stress, NPY
explained less of the variance in the more complex, self-rated pain
and affective response phenotypes. NPY diplotypes accounted for 3%
of the variance in subjective pain (McGill Pain Questionnaire sensory
subscale) and 5% of the variance in emotional experience (Positive
and Negative Affectivity Scale negative affect) (Supplementary Fig.
4).
In comparison with gene-influenced brain imaging responses in
which allele action has been evident even in small data sets12–14, trait
anxiety is a complex behaviour for which gene effects are small11, and
it is the type of gene-influenced behaviour that is perturbed by
external factors such as exposure to stress10,26. However, it is import-
ant to understand the role of NPY in complex behaviours and in
different contexts. In a relatively modest sample of 137 healthy
Finnish Caucasian controls, expression predicted by NPY diplotype















































































































































Figure 1 | Haplotype-predicted NPY expression in brain, lymphoblasts and
plasma. a, Configuration, frequencies (right) and cladistic clustering (left)
of major NPY haplotypes (H1, H2, H3, H4 and H5; frequency more than
1%) in Finnish Caucasians (n 5 516). b, Differential allele expression of NPY
mRNA showing allelic ratio (log2(C/T)) of rs5574 in 28 heterozygous human
post-mortem cerebella (Miami sample) grouped according to diplotypes
(columns 2–5, means 6 s.d.) to infer expression levels of H2, H3, H4 and H5
relative to H1 (the T allele is found only within H1, as shown in
a). Diplotypes are compared using a two-tailed t-test. Column 1 presents all
samples; column 6 shows controls for allelic amplification efficiency.
c, Expression levels of the six common diplotypes in 47 lymphoblastoid cell
lines derived from healthy Finnish Caucasians. Expression values of the
three major haplotypes (H1, H2 and H3) were calculated from observed
diplotype values (points and error bars show means 6 s.e.m.) by multiple
regression and were used to predict diplotype values (bars) under a co-
dominant model (see Supplementary Fig. 2 for details, including fit to
model). Diplotypes were grouped as low (LL), intermediate (LH) or high
(HH) in expression. Numbers above columns are n. d, Diplotype-predicted
plasma NPY levels (means 6 s.e.m., standardized with Z scores; New Haven
sample) in controls (black diamonds; LL, n 5 16; LH, n 5 113; HH, n 5 39)
and alcoholic patients (grey squares; LL, n 5 29; LH, n 5 72; HH, n 5 27). P
values were calculated by regression analysis.
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the Tridimensional Personality Questionnaire (TPQ) Harm
Avoidance subscales HA1 (Fear of Uncertainty; P 5 0.035) and
HA2 (Anticipatory Worry; P 5 0.031). There was no correlation with
the HA3 (Shyness with Strangers) or HA4 (Fatigability and Asthenia)
subscales. Diplotype-predicted NPY mRNA expression was lower in
the small number of Finnish participants with clinical anxiety dis-
orders (n 5 18) diagnosed with the Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders, 3rd edi-
tion revised (SCID), in comparison with the same 137 healthy
Finnish controls (Fig. 4b). Within Finnish participants with SCID-
diagnosed alcoholism (n 5 138), drug addiction (n 5 38), anxiety
disorders (n 5 18) and major depression (n 5 22), we observed no
correlation of NPY-diplotype-predicted expression with any of the
HA subscale scores. This may indicate dysregulation of the stress axis
in these patients; in addition, the sample sizes were not large. None of
the seven individual markers (Supplementary Fig. 1a) were assoc-
iated with HA subscales. In contrast with the larger effects of NPY
diplotype on brain functional responses, the effects of NPY on trait
anxiety were modest, accounting for 3.3% of the variance in HA1 and
3.4% of the variance in HA2. Very large study samples are required
for the consistent detection of gene effects on a complex behaviour
such as trait anxiety. We have presented converging results in which
modest effects of genes at the level of complex behaviour are sup-
ported, and mechanistically clarified, by larger effects on brain-
imaging phenotypes reflecting response to emotion and stress.
Population stratification, a potential confounding factor, was
addressed with the use of ancestry informative markers (AIMs). As
detailed (Supplementary Fig. 5), 186 highly informative AIMs were
genotyped; this process was followed by a factor analysis anchored
against a panel of 1,017 Centre d’Étude du Polymorphisme Humain
(CEPH) worldwide diversity samples representing 52 populations,
and yielding ethnic factor scores for each individual. These 186 AIMs
yielded a similar seven-factor solution to that observed27 on the basis
of short tandem repeat markers genotyped in the same populations.
Our analyses of PET pain/stress response, plasma NPY levels and
TPQ Harm Avoidance subscales were not confounded by ethnicity,
as revealed by comparisons of individuals above and below medians.



































Figure 2 | Effect of diplotype-predicted NPY mRNA expression on fMRI-
measured amygdala and hippocampal activation in response to threat-
related facial expressions. Top: statistical parametric maps representing
NPY diplotype-biased (LL . LH . HH) mean right dorsal amygdala
(x 5 16, y 5 28, z 5 214, 64 voxels, t 5 2.82, P 5 0.003) and right
hippocampal (x 5 24, y 5 220, z 5 212, 132 voxels, t 5 2.56, P 5 0.006)
activation is shown overlaid on an average sagittal and coronal MRI. Bottom:
right amygdala (black diamonds) and hippocampal (grey squares) activities
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Figure 3 | Effect of diplotype-predicted NPY
mRNA expression on pain/stress-induced
m-opioid system activation. Activation
(means 6 s.e.m.) measured by the percentage
change in the m-opioid receptor binding potential
(BP) among the NPY diplotypes (LL, n 5 8; LH,
n 5 21; HH, n 5 6) are shown in the dorsomedial
prefrontal (dmPFC) and posterior insular (pINS)
cortices, ventrolateral thalamus (vlTHA), ventral
putamen (PUT) and caudate (CAU) nuclei,
nucleus accumbens (NAC) and ventral amygdala
(AMY; Supplementary Table 1). Z scores
represented by the pseudocolour scale (left) are
superimposed on an anatomically standardized
MRI image. See also Supplementary Table 1 for
details of the localization and statistics.
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AIMs, again with no difference between low and high responders
(data not shown).
We identified a locus accounting for part of the NPY haplotype
effect by testing the four moderately common variants found in the
NPY promoter region (21016 base pairs (bp) to 63 bp; see
Supplementary Fig. 6a for details) for their ability to influence
mRNA expression. The five naturally occurring allele combinations
were inserted into a promoterless reporter gene vector (pDsRed2-1)
and NPY promoter haplotype-driven expression was analysed by
transient transfection into the raphe neuronal cell line RN46A. As
shown in Supplementary Fig. 6b and Supplementary Table 2, the
2399C allele (rs16147) accounted for a 30% decrease in basal
expression determined by comparing the allelic variations between
the promoter haplotypes. In addition, the TGins allele located at
2883 bp (rs3037354) may decrease expression, although to an extent
not reaching statistical significance. The combination of 2399C and
2883TGins reduced expression 47%. These results are consistent
with the effect of 2399C and the smaller effect of 2883TGins on
mRNA expression in post-mortem brain and lymphoblastoid cell
lines, and with the greater predictive value of haplotypes both in vitro
and in vivo (Fig. 1b, c, and Supplementary Fig. 3), and underlies our
choice to emphasize haplotype effects of NPY.
Haplotype-based association analysis maximizes the ability to cap-
ture information, haplotypes serving as proxies for unknown alleles.
However, the existence of multiple haplotypes can lead to a loss of
analytic power without some mode of clustering, for example on a
cladistic basis28. In this study we functionally grouped most NPY
haplotypes and diplotypes according to levels of expression in vivo.
There were two less common haplotypes (H4, with a frequency of
4.3%, and H5, with a frequency of 4.6%) that were excluded from
association analyses because of a lack of definitive in vivo expression
data. However, on the basis of in vitro data for both (Supplementary
Fig. 6b), and limited brain expression data for H4 (Fig. 1b), it is likely
that H4 is a low-expression haplotype and H5 is a high-expression
haplotype. In addition, the H5 haplotype uniquely contains the mis-
sense variant Leu 7RPro (rs16139C). Several studies have associated
Pro 7 with disordered glucose and lipid metabolism29,30 but not with
anxiety, and Pro 7 was not associated with anxiety in our data set
(data not shown).
We observed effects of haplotype-predicted NPY expression on
human trait anxiety and on neurobiological circuits and neurotrans-
mitter systems implicated in the regulation of emotional and stress
responses. Although the effect of haplotype-predicted NPY expres-
sion was modest for trait anxiety, consistent effects were observed
across related measures and were more evident for brain metabolic
responses to emotional images as measured with fMRI and molecular
imaging measures of the activation of the endogenous opioid system
after a stressful challenge. These findings indicate the important role
of NPY in modulating inter-individual variation in emotion and
stress resiliency, and reflect the value of a multilevel approach to
the genetic analysis of behaviour.
METHODS SUMMARY
Participants from five independent samples were analysed. A sample of 516
Finnish Caucasians was used to identify NPY haplotype configuration and link-
age disequilibrium structure, and subsamples were analysed for lymphoblast
NPY mRNA, trait anxiety, and anxiety disorders. The New Haven sample
(n 5 42) was measured for plasma NPY. The Pittsburgh sample (n 5 71)
received fMRI after an emotional probe. The Ann Arbor sample (n 5 35) under-
went [11C]carfentanil PET during a pain/stress challenge. A collection of post-
mortem brains from the Miami sample was genotyped and 28 heterozygous
cerebella were used for differential allele expression. A full description of
participants’ demographic data and psychiatric diagnoses is provided in
Supplementary Methods. Informed consent was obtained under the auspices
of human research protocols approved by institutional review boards of the
National Institutes of Health, the University of Helsinki, the University of
Pittsburgh, the University of Michigan, and Yale University. NPY genotyping
was performed with 59-nuclease assays. Genotyping with 186 AIMs was per-
formed with an Illumina 1536-SNP array. NPY mRNA quantification in lym-
phoblastoid cell lines was performed with reverse transcription (RT) followed by
TaqMan real-time PCR. Detection of allele-specific NPY expression in post-
mortem brain was performed with an RT-coupled 59 nuclease assay. Plasma
concentrations of NPY were measured by radioimmunoassay. DNAs containing
NPY promoter haplotypes were inserted into a reporter vector, pDsRed2-1, and
transfected to the RN46A cell line for the analysis of promoter variants. Details of
the fMRI emotional model, the blood-oxygenation-level-dependent (BOLD)
fMRI acquisition parameters, the experimental design for pain stressor chal-
lenge, the PET scan processes, image reconstruction, and the data analysis are
provided in Supplementary Methods.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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Figure 4 | Correlations of diplotype-predicted NPY mRNA expression with
TPQ trait anxiety and anxiety disorders in Finnish Caucasians. a, Bivariate
regression of HA1 and HA2 scores (means and s.e.m.) and diplotype-
predicted expression values in 137 healthy subjects (left to right: H1/H1,
n 5 33; H1/H3, n 5 35; H3/H3, n 5 5; H1/H2, n 5 39; H2/H3, n 5 15; H2/
H2, n 5 10). b, Diplotype-predicted NPY mRNA levels (means and s.e.m.) of
n 5 137 healthy controls and n 5 18 anxiety patients by a two-tailed t-test
(means 6 s.e.m. for HA1 and HA2 are also shown). At the top right is a
histogram comparing the numbers of controls and anxiety patients within
each of the six diplotypes.
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METHODS
Genotyping. NPY genotyping was carried out using 59-nuclease assays for six
SNP markers (rs17149106, rs16147, rs16139, rs5573, rs5574 and rs16475) in
accordance with the standard TaqMan Assay protocol (ABI). A dinucleotide
insertion/deletion polymorphism (rs3037354) was genotyped by sequencing
because of the presence of an adjacent SNP. Results were analysed on an ABI
7900 Sequence Detector, using Sequence Detection System 2.0 software.
Genotyping accuracy was verified by genotyping in a replicate 10% of samples,
randomly selected. Genotyping accuracy was greater than 0.99. Genotype com-
pletion rate was greater than 0.96. Sequencing was performed with BigDye
Terminator v3.1 reagent and analysed on an ABI 3100 sequencer. The Finnish
Caucasian sample, the PET imaging pain stress response sample (Ann Arbor)
and the sample measured for plasma NPY levels (New Haven) were also geno-
typed with AIMs with the use of a GoldenGate Assay (Illumina) 1,536-marker
array. The marker selection was based on the HapMap Project reference allele
frequency (RAF) among European Caucasians, Asians, and Africans (Yoruban).
Selected markers have an RAF difference greater than 0.7 and RAF ratio larger
than 10:1 between at least one pair of the continental populations and is balanced
to distinguish between continental populations31.
NPY mRNA quantification by real-time PCR. Total RNA was isolated from
lymphoblastoid cell lines derived from healthy Finnish men with TRIzol reagents
(Invitrogen). RNA samples were treated with RNase-free DNase (Ambion) to
remove contaminating DNA. NPY mRNA quantification was performed with a
two-step TaqMan real-time RT–PCR assay. Total RNA (1mg) was reverse-tran-
scribed into cDNA with a Cloned AMV First-Strand cDNA Synthesis Kit and
random hexamers as primers, following the manufacturer’s instructions. cDNA
(3ml) was applied in 25ml of a TaqMan real-time PCR reaction on an ABI 7700
Sequence Detector with the ABI Assay-on-demand gene expression kit and using
b-actin as an endogenous control for normalization. Signals were analysed with
Sequence Detector System software 2.0. Relative NPY mRNA expression was
calculated by the formula 2{DDCt , where DCt is the difference in Ct (PCR cycle
number when signal has reached the threshold) between NPY and b-actin. A
triplicate of each sample was used to determine each measurement and the assay
was repeated at least three times.
Detection of allele-specific expression of human NPY in cerebellum.
Differential allelic expression analysis was performed with a RT-coupled 59
nuclease assay. A coding SNP, rs5574 (C/T) located in NPY exon 3, was selected
as an endogenous reporter for the assay (see Supplementary Table 3 for primer/
probe sequences). Total RNA (1mg) extracted from post-mortem cerebella of
individuals heterozygous at rs5574 was reverse-transcribed. cDNA (2 ml) was
used in a 25-ml reaction for TaqMan real-time PCR. For the control of amp-
lification efficiency, a template with an artificial 1:1 allelic ratio, constructed by
inserting one copy each of the cDNA amplicon containing either the C allele and
T allele in tandem into the pDsRed2-1 plasmid, was also assayed on the same
plate. The principle and the method of computation of allele expression ratios
were described previously32.
Quantification of plasma NPY. Blood samples were obtained at 08:45 (45 min
after placement of the intravenous catheter) and every 15 min thereafter for a
total of eight time points under the neutral condition. Plasma concentrations of
NPY were measured by using our previously well-characterized double-antibody
radioimmunoassay with 125I-NPY as the tracer33. The working range of the NPY
assay is 19.5–1,250 pg ml21, and the assay sensitivity is about 15 pg ml21. The
intra-assay and inter-assay coefficients of variation are about 4% and 14%,
respectively. NPY concentrations were standardized with the Z score to mini-
mize between-assay variation.
Report gene constructs and transfection assays. Human NPY promoter and
upstream regulatory region (from 21016 bp to 63 bp) were amplified by PCR in
a 50-ml volume from genomic DNA of individuals who were either homozygous
or heterozygous for the five common haplotypes of the region. The PCR frag-
ments were digested with both Xho I and HindIII restriction enzymes, and ligated
into the multiple cloning sites upstream of the DsRed protein reporter gene of
the pDsRed2-1 plasmid (BD Biosciences). Ligation products were used to trans-
form 50ml of TOP10 competent cells (Invitrogen). Plasmid DNAs were
extracted, and clones with an insert of the correct size were verified by DNA
sequencing. For transfection analysis, RN46A cells were grown in 50% DMEM
medium and 50% Ham’s F-12 medium supplemented with 10% FBS. Cells were
plated out 24 h before transfection at a density of 5 3 105 cells per well in 24-well
plates, and each group of samples was plated in triplicate wells. The constructed
NPY promoter haplotype-pDsRed plasmid DNA (1.6mg) and green fluorescent
protein (GFP) plasmid DNA (0.05mg), used as a transfection efficiency control,
were co-transfected into the cultured cells with Lipofectamine 2000 (Invitrogen)
in accordance with the manufacturer’s instructions. pDsRed vector DNA with-
out a NPY promoter insert was also used for each transfection as a negative
control. Both red (DsRed protein reporter gene) and green (GFP) fluorescent
signals were captured through a fluorescent microscope with the use of OpenLab
software (Improvision), 48 h after transfection. For each well of the transfected
cells, ten fields of signals were captured across the same centre areas of the well,
and a total of 30 fields of both red and green signal were captured for each group
of cells. For each field red and green fluorescent signals were measured in the
same region of interest (ROI) with the red signal of each field normalized against
the green signal. The transfection analysis was repeated at least three times. The
mean and standard deviation of reporter gene signal were calculated for each
promoter haplotype group, and the expression levels were compared between
haplotypes by using a t-test (two-tailed).
Data analysis. Genotype distributions were tested at each polymorphic locus for
departure from Hardy–Weinberg equilibrium. Pairwise linkage disequilibrium
coefficients (D9) were estimated and linkage disequilibrium block structures
were evaluated with Haploview34. A minimum average D9 value of 0.80 was used
to define block boundaries (however, the average D9 in most blocks was sub-
stantially higher). Maximum-likelihood estimates of haplotypes and frequencies
were determined with PHASE v2.02 (ref. 35), and diplotypes were assigned to
each individual. For haplotype cladistic clustering, the Manhattan distances
among haplotypes were calculated with a modified metric in which more weight
was given to markers with higher minor allele frequency and to markers with
higher r2 values to neighbouring markers (Q.Y., unpublished observations).
Continuous variables were compared among diplotype groups by a two-tailed
t-test, analysis of variance, and regression analysis, and are presented as
means 6 s.e.m.
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